Organ-specific pancreatic tumor growth properties and tumor immunity

Keita Morikane, Richard M Tempero, Connie L. Sivinski, Mitsuharu Nomoto, Michelle L. Van Lith, Tetsuichiro Muto, Michael A Hollingsworth

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

We established a model of orthotopic injection of a syngeneic pancreatic tumor cell line in C57BL/6 mice and evaluated the effects of organ site on induction of immunity to a tumor-specific antigen, MUC1. Mice were challenged with a syngeneic pancreatic adenocarcinoma cell line that expressed MUC1 (Panc02-MUC1) by orthotopic injection into the pancreas, or by subcutaneous injection. Tumor cells injected into the pancreas grew much faster than those injected subcutaneously. Mice challenged subcutaneously with Panc02-MUC1 rejected tumors or developed slowly growing tumors that were negative for MUC1 expression. In contrast, mice challenged orthotopically into the pancreas developed progressive tumors that were positive for MUC1 expression. Sera from mice that rejected Panc02-MUC1 (tumor-immune mice) showed no detectable IgG1 and IgM titers against the MUC1 tandem-repeat peptide, whereas mice with progressive tumor growth had significant titers of IgG1 and IgM specific for MUC1. This suggests that the humoral immune response was ineffective in mediating tumor rejection. The results show that the growth properties and immunological rejection of pancreatic tumors is affected by the organ site at which the tumor grows.

Original languageEnglish (US)
Pages (from-to)287-296
Number of pages10
JournalCancer Immunology Immunotherapy
Volume47
Issue number5
DOIs
StatePublished - Feb 9 1999

Fingerprint

Immunity
Growth
Neoplasms
Pancreas
Immunoglobulin M
Immunoglobulin G
Injections
Neoplasm Antigens
Subcutaneous Injections
Humoral Immunity
Tumor Cell Line
Inbred C57BL Mouse
Adenocarcinoma
Cell Line
Serum

Keywords

  • Orthotopic injection MUC1
  • Pancreatic tumor
  • Syngeneic
  • Tumor immunity

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Cite this

Organ-specific pancreatic tumor growth properties and tumor immunity. / Morikane, Keita; Tempero, Richard M; Sivinski, Connie L.; Nomoto, Mitsuharu; Van Lith, Michelle L.; Muto, Tetsuichiro; Hollingsworth, Michael A.

In: Cancer Immunology Immunotherapy, Vol. 47, No. 5, 09.02.1999, p. 287-296.

Research output: Contribution to journalArticle

Morikane, Keita ; Tempero, Richard M ; Sivinski, Connie L. ; Nomoto, Mitsuharu ; Van Lith, Michelle L. ; Muto, Tetsuichiro ; Hollingsworth, Michael A. / Organ-specific pancreatic tumor growth properties and tumor immunity. In: Cancer Immunology Immunotherapy. 1999 ; Vol. 47, No. 5. pp. 287-296.
@article{7ad7e5722495405babaf402063e334ee,
title = "Organ-specific pancreatic tumor growth properties and tumor immunity",
abstract = "We established a model of orthotopic injection of a syngeneic pancreatic tumor cell line in C57BL/6 mice and evaluated the effects of organ site on induction of immunity to a tumor-specific antigen, MUC1. Mice were challenged with a syngeneic pancreatic adenocarcinoma cell line that expressed MUC1 (Panc02-MUC1) by orthotopic injection into the pancreas, or by subcutaneous injection. Tumor cells injected into the pancreas grew much faster than those injected subcutaneously. Mice challenged subcutaneously with Panc02-MUC1 rejected tumors or developed slowly growing tumors that were negative for MUC1 expression. In contrast, mice challenged orthotopically into the pancreas developed progressive tumors that were positive for MUC1 expression. Sera from mice that rejected Panc02-MUC1 (tumor-immune mice) showed no detectable IgG1 and IgM titers against the MUC1 tandem-repeat peptide, whereas mice with progressive tumor growth had significant titers of IgG1 and IgM specific for MUC1. This suggests that the humoral immune response was ineffective in mediating tumor rejection. The results show that the growth properties and immunological rejection of pancreatic tumors is affected by the organ site at which the tumor grows.",
keywords = "Orthotopic injection MUC1, Pancreatic tumor, Syngeneic, Tumor immunity",
author = "Keita Morikane and Tempero, {Richard M} and Sivinski, {Connie L.} and Mitsuharu Nomoto and {Van Lith}, {Michelle L.} and Tetsuichiro Muto and Hollingsworth, {Michael A}",
year = "1999",
month = "2",
day = "9",
doi = "10.1007/s002620050533",
language = "English (US)",
volume = "47",
pages = "287--296",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "5",

}

TY - JOUR

T1 - Organ-specific pancreatic tumor growth properties and tumor immunity

AU - Morikane, Keita

AU - Tempero, Richard M

AU - Sivinski, Connie L.

AU - Nomoto, Mitsuharu

AU - Van Lith, Michelle L.

AU - Muto, Tetsuichiro

AU - Hollingsworth, Michael A

PY - 1999/2/9

Y1 - 1999/2/9

N2 - We established a model of orthotopic injection of a syngeneic pancreatic tumor cell line in C57BL/6 mice and evaluated the effects of organ site on induction of immunity to a tumor-specific antigen, MUC1. Mice were challenged with a syngeneic pancreatic adenocarcinoma cell line that expressed MUC1 (Panc02-MUC1) by orthotopic injection into the pancreas, or by subcutaneous injection. Tumor cells injected into the pancreas grew much faster than those injected subcutaneously. Mice challenged subcutaneously with Panc02-MUC1 rejected tumors or developed slowly growing tumors that were negative for MUC1 expression. In contrast, mice challenged orthotopically into the pancreas developed progressive tumors that were positive for MUC1 expression. Sera from mice that rejected Panc02-MUC1 (tumor-immune mice) showed no detectable IgG1 and IgM titers against the MUC1 tandem-repeat peptide, whereas mice with progressive tumor growth had significant titers of IgG1 and IgM specific for MUC1. This suggests that the humoral immune response was ineffective in mediating tumor rejection. The results show that the growth properties and immunological rejection of pancreatic tumors is affected by the organ site at which the tumor grows.

AB - We established a model of orthotopic injection of a syngeneic pancreatic tumor cell line in C57BL/6 mice and evaluated the effects of organ site on induction of immunity to a tumor-specific antigen, MUC1. Mice were challenged with a syngeneic pancreatic adenocarcinoma cell line that expressed MUC1 (Panc02-MUC1) by orthotopic injection into the pancreas, or by subcutaneous injection. Tumor cells injected into the pancreas grew much faster than those injected subcutaneously. Mice challenged subcutaneously with Panc02-MUC1 rejected tumors or developed slowly growing tumors that were negative for MUC1 expression. In contrast, mice challenged orthotopically into the pancreas developed progressive tumors that were positive for MUC1 expression. Sera from mice that rejected Panc02-MUC1 (tumor-immune mice) showed no detectable IgG1 and IgM titers against the MUC1 tandem-repeat peptide, whereas mice with progressive tumor growth had significant titers of IgG1 and IgM specific for MUC1. This suggests that the humoral immune response was ineffective in mediating tumor rejection. The results show that the growth properties and immunological rejection of pancreatic tumors is affected by the organ site at which the tumor grows.

KW - Orthotopic injection MUC1

KW - Pancreatic tumor

KW - Syngeneic

KW - Tumor immunity

UR - http://www.scopus.com/inward/record.url?scp=0032951068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032951068&partnerID=8YFLogxK

U2 - 10.1007/s002620050533

DO - 10.1007/s002620050533

M3 - Article

C2 - 10022473

AN - SCOPUS:0032951068

VL - 47

SP - 287

EP - 296

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 5

ER -